Biologics for autoimmune disease at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

15 organizations at PEGS Europe 2026 present work in autoimmune disease: 10 drug developers, 3 suppliers and service providers and 2 academic, government and non-profit bodies. Between them they bring 36 presentations to the program. Most represented: Roche (8 on the program), Regeneron (4 on the program), Genentech (4 on the program). As of Oct 8, 2026.

All 541 organizations at PEGS Europe 2026 →

Showing 1–11 of 15 organizations

Organization	PEGS Europe 2026 Attendance
Roche Basel, Switzerland
roche.com Large pharma Swiss pharmaceutical and diagnostics company whose research units discover and develop antibodies, bispecifics and other biologic medicines.	Chair Tue Nov 17 8:25am–8:30am Chairperson's Remarks Optimisation & Developability Talk Tue Nov 17 11:45am–12:15pm Elucidating the Structure-PK Relationship of Complex Antibody Formats and Understanding the Underlying Mechanisms for Improved Drug Design Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Tue Nov 17 2:05pm–2:35pm From Molecules to Drug Readiness Optimisation & Developability Talk Wed Nov 18 9:30am–10:00am Characterisation of a Biparatopic Sweeping Antibody Biologics for Autoimmune Diseases Talk Wed Nov 18 2:35pm–3:05pm Next-Generation T Cell Engagers: Leveraging Protease Activation to Overcome Toxicity and Expand the Therapeutic Window Advancing Multispecific Antibodies and Combination Therapy to the Clinic Talk Wed Nov 18 2:35pm–3:05pm Novel Orthogonal Receptor Platform Activating the IL12 Pathway in CAR-T Cells Using a Small-Molecule Ligand Advances in Immunoengineering Talk Wed Nov 18 6:25pm–6:50pm Robust Production of Virus-Like Particles in HEK293 Cell Lines Designing High-Performance Expression Platforms Talk Thu Nov 19 11:15am–11:45am Next-Generation FVIIIa-Mimetic Bispecific Antibody NXT007 for Hemophilia A: Evaluation in Preclinical Models Engineering the Next Generation of Bispecific Antibodies Talk Thu Nov 19 11:45am–12:15pm Insights into Fab Nebulisation: How to Minimise Aggregates for Inhaled Biologics Protein Stability & Formulation
Regeneron Tarrytown, NY
regeneron.com Large pharma Biotechnology company with marketed antibody medicines, discovered with its VelocImmune mice, and a pipeline including CD3 bispecifics.	Talk Tue Nov 17 11:15am–11:45am Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumour Activity of CD3-Engaging Bispecific Antibodies Safety and Efficacy of Bispecific and Multispecific Antibodies Chair Wed Nov 18 8:25am–8:30am Chairperson's Remarks Advancing Multispecific Antibodies and Combination Therapy to the Clinic Chair Wed Nov 18 2:00pm–2:05pm Chairperson's Remarks Advancing Multispecific Antibodies and Combination Therapy to the Clinic Talk Wed Nov 18 2:35pm–3:05pm A Novel Approach to Enhance Tissue Specific Gene Delivery Biologics for Autoimmune Diseases Talk Wed Nov 18 6:00pm–6:30pm Advancing CD3 Bispecifics for Solid Tumour Indications Engineering Antibodies & Beyond
Genentech South San Francisco, CA
gene.com Large pharma Roche group biotechnology company discovering and developing antibody and protein medicines in oncology, immunology and other areas.	Talk Tue Nov 17 11:45am–12:15pm Multi-Objective Antibody Optimisation with Property Enhancer (PropEn) Optimisation & Developability Talk Wed Nov 18 2:05pm–2:35pm AI-Based Analysis of Label-Free Live Cell Imaging of T Cell Mediated Tumour Killing Assay Enables Competitive and Robust Hit Calling Analytical Characterisation of Biotherapeutics Talk Wed Nov 18 6:30pm–7:00pm SMACk: A Modular Platform for Sterically Masked Activated Cytokines Biologics for Autoimmune Diseases Talk Thu Nov 19 2:35pm–3:05pm Comparative Analysis of 4-1BB and CD28 Tumour-Targeted Co-Stimulation to Support T Cell Bispecific Antibody Therapy in Solid Tumours Engineering the Next Generation of Bispecific Antibodies
Zymeworks
zymeworks.com Biotech Clinical-stage biotech developing multispecific antibodies and antibody-drug conjugates for cancer and inflammatory diseases; created the Azymetric bispecific platform.	Talk Tue Nov 17 2:05pm–2:35pm Next-Generation Tumour-Targeted Masked Cytokines for Enhanced Tolerability and Localised Anti-Tumour Activity Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Tue Nov 17 2:05pm–2:35pm TriTCE Co-Stim: A Differentiated T Cell Engager Platform with Conditional Cis CD28 Co-Stimulation and Transferability to Diverse Targeting Strategies T Cell Engagers Talk Wed Nov 18 9:00am–9:30am Engineering Simultaneous Targeting of IL-4Ra and IL-33 Pathways to Broadly Suppresses Autoimmune Inflammation Biologics for Autoimmune Diseases
FairJourney Biologics Porto, Portugal	◆Corporate Sponsor
fjbio.com CRO & CDMOCorporate Sponsor Antibody discovery and engineering CRO running phage display, immunisation and optimisation campaigns for drug developers.	Booth Exhibiting at Booth 325 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Talk Wed Nov 18 10:00am–10:30am Talk Title to be Announced Engineering Antibodies & Beyond Chair Wed Nov 18 2:00pm–2:05pm Chairperson's Remarks Biologics for Autoimmune Diseases
Immunocore Abingdon, UK
immunocore.com Biotech Develops TCR bispecific medicines for cancer and autoimmune disease, with a marketed melanoma therapy.	Talk Tue Nov 17 9:30am–10:00am Engineering Specific and Potent T Cell Engagers Targeting pHLA Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Wed Nov 18 7:00pm–7:30pm IMC-S118AI: beta-cell Targeted Bispecific for Type 1 Diabetes (T1D) Disease Modification Biologics for Autoimmune Diseases
Cullinan Therapeutics Cambridge, MA
cullinantherapeutics.com Biotech Biotech developing T cell engagers and other targeted therapies for autoimmune diseases and cancer.	Talk Wed Nov 18 11:45am–12:15pm A New Frontier for the Treatment of Autoimmune Diseases: T Cell Engager Therapies Targeting CD19 or BCMA Biologics for Autoimmune Diseases Talk Wed Nov 18 4:00pm–4:10pm The Future of T Cell Engagers Plenary Bispecifics, multispecifics and T cell engagersOncology and immunotherapy Panel Wed Nov 18 4:10pm–4:50pm Emerging Modalities and the Future of Antibody Engineering Plenary · with Stanford University, University of Stuttgart, Johnson & Johnson Innovative Medicine Protein and antibody engineering
Seismic Therapeutic
seismictx.com Biotech Clinical-stage immunology biotech using machine learning to design biologics for autoimmune, inflammatory and allergic diseases.	Chair Wed Nov 18 8:25am–8:30am Chairperson’s Remarks Biologics for Autoimmune Diseases Talk Wed Nov 18 11:15am–11:45am Targeting IgE via Multiple Novel Mechanisms in IgE Mediated Allergic and Atopic Diseases Biologics for Autoimmune Diseases
University College Dublin Dublin, Ireland
	Talk Wed Nov 18 6:00pm–6:30pm Targeting Leukocyte Trafficking Upstream of α4β7: Antagonism of the Cannabinoid GPCR CB2R as a Therapeutic Mechanism in Crohn's Disease Biologics for Autoimmune Diseases Chair Thu Nov 19 8:25am–8:30am Chairperson’s Remarks Antibodies Against Challenging Targets
ACROBiosystems	◆Corporate Sponsor
acrobiosystems.com Reagents & consumablesCorporate Sponsor Supplies recombinant target proteins, antigens and assay kits for antibody discovery, screening and characterisation.	Booth Exhibiting at Booth 232 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Talk Wed Nov 18 10:00am–10:15am Talk Title to be Announced Biologics for Autoimmune Diseases
Evaxion Hørsholm, Denmark	◆Corporate Sponsor
evaxion.ai BiotechCorporate Sponsor Danish biotech using its AI-Immunology platform to design vaccines and immunotherapies for cancer and infectious diseases.	Talk Wed Nov 18 10:15am–10:30am Talk Title to be Announced Biologics for Autoimmune Diseases